Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf3 – 500 . " 6 " 5-10 per os +1 2 .
" & :
1.*? 500 , 1000 ; 250 ; 500
2.* & 3% 25 , 40
3.*+ 20 .
" & & :
,- ! : % ,%
/ , & :
1.@ & . JB+BL>! B> > 6>+@?/BB $#" .- 6 , « -6 ».- 2002.- .523-524
2.G . " .- 6 , « -6 ».- 2002.- .576-
3.National Guideline Clearinghouse. Practice Managment for Prophylactic Antibiotic Use in Open Fracture: Eastern Association for the Surgery of Trauma.- 2000.- p.28
4.National Guideline Clearinghouse. Preoperative Test: the Use of Routine Preoperative Tests for Elective Surgery: Evidence, Methods&Guidance. London.-NICE.- 2003. 108p.
* – , # (% % ) .
8 , & !
: 09-126
"$ &: " :
& ! : &$ " , # 6D , " % & % , " " %
' & & ( ): 15
(:
C50 ) " " %
) : 8 – 3 " " % .
$ |
: |
' |
# |
|
|
& & "$ |
||
$ 6 % $, |
|
|
||||||
|
TNM |
% |
|
$ (2002 .). |
! |
|
||
|
|
" & , " |
|
|||||
(pTNM). & % ,% " % .
' " " "-% " % ,% & & ;. !" % , % & , " & % & " " .
* : , % , " " % , " 6D, & , & ( , & & ), " " , # % , " , , % , &" % , " / , " % .
" :
" : , " .
5 : "
" , ? (6 |
), ?6, & /$ |
|||||
(9 ), & , 7 , _ R- , H)B " |
||||||
% , , |
" , , . @ , 6 ;, ; |
|||||
" % , |
(7 -, 7 +, Her-2-neu), |
, !?15-3 |
||||
% |
. |
|
|
|
||
|
: V - " " % , & |
|||||
|
|
" & &, |
|
( |
|
|
), & |
|
( ); |
V |
– |
||
" % , |
, , % , |
|||||
% « & », % " % , , & " % , " / . @ & & , , " % , , , .
" & :
2."
3." 3 _
4.! 7
6."
7.# "
8.#
11.1 ( , , , " , " & , )
12."
13.$
14.?J;
15.?!;
16.;
17. -
18.H)B $
19.7
20.H)B " %
21.6
22.@
23.H)B
24.6 ; " %
25.; " %
" & :
+ : &$ "" % ( 6D) % "
|
% &. |
3 |
|
|||||
( , |
) |
|
|
|
|
3 |
||
$# 6D. 3 |
$ & |
|||||||
|
|
, |
, |
|
, |
$# |
||
# 3 . ? ,
, 3 |
- |
. |
|||||||
? , |
, |
3 |
- |
. |
|||||
? % |
" " . |
||||||||
3 $ |
3 . |
+ |
|
||||||
( , , ) ( ) |
3 |
|
|||||||
$ |
% $ |
" 3 . |
|||||||
|
( , ) & % |
3 |
|
||||||
. > |
|
|
|||||||
, |
" . |
||||||||
, " ( , ) |
" |
||||||||
|
( ) 3 , |
|
|
|
|||||
. |
|
|
|
|
|
|
|
|
|
|
( , |
) " |
|
|
|||||
& 6D $ & %% , % .
|
, W |
||
1.+ : |
, |
" , " |
|
( |
3 ) |
|
|
|
$ # : - " 100 |
/ 2 1 |
|
% 3 |
|
|
|
- . |
|
||
, " , $" 100 / 2 1 % 3 .
, " &$ $ $# & – (100 / 2 1 % 3 )
|
(175 / 2 3 % 3 ); - |
||
|
" , |
- " |
|
" 75% |
. @ |
||
" & " . |
|||
2. |
: % 70 " |
|
|
$# , $# & |
" |
||
&$ $
|
" , |
|
950 / 2 % % |
|
(75% ) & 1 14 |
$ 75 / 2 / & |
|||
|
1 |
21 . , |
" / |
|
|
" ()1250 / % % 1 14 21- |
|||
.
3. ( $ $: , &( , , 3 ) " / , & - / . '" .
4. > : –" 6D % # & . ; & .
! ( $# 6D):
* – ( 100 / 2 & 1- 14 &),( 400 / 2 / 1- 8- ) 5- ( 600 / 2 / 1- 8- ) % 4 , " % & 6.
9 #* – ( 500 / 2 / ), - ,( 50 / 2 / ) 5- ( 500 / 2 / ) % 3 ," " % & 6.
9 * – 5-, 3 % 3 ," " % & 6.
9 *# – 5-, (3 ) % 3 , " " % & 6.
! ( $# 6D), $"$# , & 3 , " , 5- (/6_). ! "( / 2 % 3-4 " 4-6 . ( /6_) % &. ? V$ 3 & .6D & % 50 "$ % &. , $"$# ( , , , 3 , ) % "6D " " $$ % &. @ & ( 5 ) V$ %& 3 6D. 5
( 5 ) 3 . |
|
|
|||
6 - " |
" |
|
|
, |
$ |
%$ " /6_. |
|
|
|
|
|
" /6_ – |
, |
||||
5-. |
|
|
|
|
|
! _?/ – |
5-, ( ) |
||||
. |
|
|
|
|
|
@ " |
|
|
|
||
& 400 \ " 10 . |
|
||||
? " " % .
/ W . ) .
1.H " %
2.B " &"
3.' % &"$
% ?
|
|
4. ' |
|
7. J$ 3
9.B & |
|
|
% |
||
|
||
$ |
|
|
? |
|
11.? &.
12.) ?
? = ?
5.' |
|
|
|
6. 6 3 |
|||
"$ $? |
|
||
|
|
||
|
|
|
|
|
|
|
8. 6 3" %
10. ! !$ 0 ?"
13.
14.
15. ! !$ I ? |
|
|
|
16.! !$ II III ? |
|
" |
|
" |
|
|
|
/ W .
9 I #
22.! I
23.'
24.! " % ( )?
? = ?
25., G;
26.B
/ W .
9 II III #
? = ?
27.! 2 3
28.'
29. ! " % ( )?
|
30 c 3 " |
|
31. , G; |
|
|
XRT ? |
? |
32. B
/ W .
9 0 #
? = ?
17.! 0 ($"$ in situ)
18.' .
19. ! " % ( )?
20. .
21. B .
" & :
1.400
2.*? 50 , 100 , 500 .; 5%, 10% 2 , 5 .
3.*@ 5% 400
4.+ &" " &
5.3,6
6.*6 2,5 .
7. |
*/ % 50 ; V 200 |
|
|
, 500 |
|
8. |
*@ 10 , 50 |
|
9. |
*/ |
10 , 25 , 50 |
10. |
*' |
V 1 |
11.*7 50 , 100 ; V 100 /5
12.*7 V10 , 50
13.*; 10 , 20
14.*B & 150 – 10 \ .
" & & :
,- ! : & ( )
|
, " 3 " |
/ , |
& : |
1.Breast cancer treatment. Institute for Clinical Systems Improvement (ICSI). Breast cancer treatment. Bloomington (VN): Institute for Clinical Systems Improvement (ICSI); 2004 Sep. 41 p. [77 references]
2.Adjuvant Systemik Therapy for Node-negative Breast Cancer. Practic Guideline Report #1-8. Most Recent Literature search: May 1, 2003
3.The role of the Taxanes in the Management of Metastatic Breast cancer. Practic Guideline Report #1-3. April 24, 2004
4.Capecetabine in Stage IY Breast Cancer. Practic Guideline Report #1-16. Version 2, 2003
5.The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast cancer. Practic Guideline Report #1-11. (Version 2.2002)
6.Practic Guideline Report #1-5. Recommendations modified: October 2003
7.@ & . >% " . 2003, .2, " &5.
* – , # (% % )
+ , , "<), ! &
: 02-020
"$ &: " :
& !: , , & .
' & & ( ): 9
(:
S05.5 $# c T15 B % "
T15.0 B
T15.1 B V$&
T15.8 B & % " T15.9 B " % "
) : + - $#
$ :
1. % & % : $# , , ;
2.: , "-& , .
3.% : # , # .
4." : " , " .
5. , : , , &, " ; – , , , " .
" |
: 3 |
||
|
|
|
: & , " , % , |
&, |
. |
||
" & : |
|||
1. |
< |
#&$ # |
|
2.&
4.H)B
6.7
7.'
8.# (6 )
9.# "
10.B
11.$
12.?J;
13.?!;
14.&
" & & :
1.;
2.B " " &
3.7
4.7
5.6